Liquid Biopsies: Paving the Way for More Personalized and Responsive Cancer Care

ABSTRACT

_Chief of Early-Phase Drug Development_ Vivek Subbiah joined the Sarah Cannon Research Institute (SCRI) in Nashville in 2023 as chief of early-phase drug development, where he leads the Institute’s early-phase drug development capabilities and programs. Previously, Dr. Subbiah held several leadership roles at the University of Texas MD Anderson Cancer Center, including executive director of medical oncology research in the MD Anderson Cancer Network and clinical medical director of the Division of Cancer Medicine. He is a major advocate for precision oncology and has designed and led several first-in-human trials that have resulted in FDA approval.